224946-85-4

Upstream product

• 3977-29-5 2-amino-6-methyl-3H-pyrimidin-4-one 
• 4214-85-1 2-amino-6-methyl-5-nitro-4(3H)-oxopyrimidine 
• 100-39-0 benzyl bromide 
• 151587-54-1 2-<<(N,N-Dimethylamino)methylene>amino>-6-methyl-5-nitro-4(3H)-oxopyrimidine 

Downstream Products

• 224946-90-1 C₃₂H₂₆N₆O₁₀ 
• 224946-87-6 1-benzyl-2'-deoxy-3',5'-di-O-(p-nitrobenzoyl)-9-deazaguanosine 
• 224946-89-8 1-benzyl-2'-deoxy-9-deazaguanosine 
• 224946-91-2 2-Amino-3-benzyl-7-((2S,4S,5R)-4-hydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)-3,5-dihydro-pyrrolo[3,2-d]pyrimidin-4-one 
• 224946-94-5 N′-(3-benzyl-4-oxo-4,5-dihydro-3H-pyrrolo-[3,2-d]pyrimidin-2-yl)-N,N-dimethylformimidamide 
• 224946-82-1 2-amino-3-benzyl-3,5-dihydro-4H-pyrrolo[3,2-d]pyrimidin-4-one 
• 224946-80-9 3-benzyl-2-dimethylaminoethyleneimino-5-nitro-6-β-dimethylaminovinyl-3H-pyrimidin-4-one 

Relevant academic research and scientific papers

Synthesis of a novel C-nucleoside, 2-amino-7-(2-deoxy-β-D-erythro- pentofuranosyl)-3H,5H-pyrrolo-[3,2-d]pyrimidin-4one (2'-deoxy-9- deazaguanosine)

A synthesis of the C-nucleoside, 2-amino-7-(2-deoxy-β-D- erythropentofuranosyl)-3H,5H-pyrrolo[3,2-d]pyrimidin-4-one (9-deaza-2'- deoxyguanosine) was achieved starting from 2-amino-6-methyl-3H-pyrimidin-4- one (5) and methyl 2-deoxy-3,5-di-O-(p-nitrobenzoyl)-D-erythro-pento- furanoside (11). The anomeric configuration of the C-nucleoside was established by 1H NMR, NOEDS and ROESY. This C-nucleoside did not inhibit the growth of T-cell lymphoma cells.